A human trial puts senolytics to the test
Plus: NAD+ and the brain’s cellular antennas, happiness, blood pressure, and life inside the cell.
Elysium Abstract <[email protected]>
Share
Elysium Health promotes a human trial testing senolytics, a longevity science concept, in a randomized trial. The trial aims to clear damaged cells while sparing healthy ones, with results showing improved liver fibrosis and resolved metabolic dysfunction-associated steatohepatitis in participants. Elysium Health shares these findings in their newsletter, The Abstract.
What the raw message shows
From the headers
- Sent with
-
Klaviyo See it in the headers
In the HTML
- Built with
- Animated GIFs, Dark-mode styles
Across Elysium Health's email
- Sends
- About 2 a week
- DMARC
-
Enforced, quarantine
Mail failing authentication goes to spam.
The copy
512 words · about 2 min to read · 2 buttons
Thanks for reading The Abstract. This month’s edition is 1,149 words, about a 4-minute read.
Is there a topic that you’d like to see more of in The Abstract? Drop us a line at [email protected]. Want to get The Abstract in your inbox? Sign up here.
The Abstract
This month, researchers test one of longevity science’s boldest ideas in a human randomized trial, microscopists reveal the astonishing machinery inside living cells, and a mouse study connects NAD+ with the tiny “antennas” that help neurons maintain cellular health. We’re also reading what 600 collective years of happiness research taught the scientists themselves—and why blood-pressure advice may need to focus on what we add to our diets as well as what we remove.
A human trial puts senolytics to the test
Cellular senescence is a stress response that permanently stops damaged cells from dividing. As senescent cells build up with age, they can release inflammatory signals that disrupt nearby tissue. Senolytics aim to clear these cells while sparing healthy ones.
Small early studies paired two senolytics: dasatinib (D), a prescription cancer drug, and quercetin (Q), a plant compound in the flavonoid family found in apples and onions. They focused on safety and markers of senescence. A new phase 2 trial randomly assigned 31 people with metabolic dysfunction-associated steatohepatitis (MASH), a liver disease marked by inflammation and scarring, to receive the D+Q combination intermittently or a placebo.
After 21 weeks, liver biopsies showed that fibrosis improved by at least one stage without worsening MASH in 47% of the treatment group versus 7% of the placebo group. MASH resolved in 53% versus 7%, respectively. Gene activity linked to senescence and fibrosis also declined in liver cells.
Adverse events were more common with treatment—reported by 82% of participants versus 43% of those receiving placebo—although researchers said they were temporary and resolved without ongoing treatment. The findings suggest that targeting cellular senescence, a hallmark of aging, may improve disease outcomes in people. But larger, longer trials across multiple sites are needed to confirm the liver benefits and determine whether they outweigh the risks.
The Expert’s Take:
“This study represents an encouraging step toward translating our understanding of cellular senescence into meaningful clinical benefits. What makes these findings particularly compelling is that the improvements in liver health were accompanied by molecular changes consistent with reduced senescence and fibrosis. While the trial was small and the higher incidence of adverse events warrants caution, the results provide early evidence that targeting a fundamental mechanism of aging may have therapeutic benefits. Larger studies will be essential to establish the long-term safety and efficacy of this D+Q approach.”
Button Lynne Chang, Ph.D.
VP, Product Development, Elysium Health
Button Read more
THIS MONTH
What We’re Reading
These are third-party articles about science that we find interesting but have no relationship to Elysium or any of our products. Elysium’s products are not intended to screen, diagnose, treat, cure, or prevent any disease.
Mitochondria (blue) and actin (white) interacting in dividing cells. Andrew Moore/Howard Hughes Medical Institute. Courtesy of Nikon Small World
The hidden life inside a cell
The words as text: what a screen reader can follow, and all there is when images don't load.
What the headers say
Read from the message's own headers, as it arrived.
- Came from
-
o1385.shared.klaviyomail.com
· 149.72.236.79
Klaviyo's sending servers
- SPF
- Pass for send.elysiumhealth.com
- DKIM
-
- Pass signed by elysiumhealth.com
- DMARC
-
Pass for elysiumhealth.com
Policy: quarantine
- Unsubscribe
-
One-click
Meets the Gmail and Yahoo rule for bulk senders.
- Complaints
- No feedback-loop header
Show all 21 headers Hide the headers
As received, minus the delivery side: the archive's own addresses show as [recipient], its mail servers as [receiver], signatures are left out and unsubscribe links trimmed to their host.
Route
- Received Identifies Klaviyo
- from o1385.shared.klaviyomail.com (149.72.236.79) by [receiver] (cloudflare) id 0Mj5ftwhTgam for <[recipient]>; Sun, 22 Nov 2026 13:15:54 +0000
- Received
- by recvd-7fd4c8c657-x8769 with SMTP id recvd-7fd4c8c657-x8769-1-6B02EB09-A6 2026-11-22 13:15:53.801861006 +0000 UTC m=+997395.657788206
- Received
- from MjAwMDcxNDM (unknown) by geopod-ismtpd-18 (SG) with HTTP id 5F40pgJAT0WwpxiayF2pHA Sun, 22 Nov 2026 13:15:53.779 +0000 (UTC)
Authentication
- Received-SPF Authentication result
- pass ([receiver]: domain of bounces+20007143-b269-elysiuminboxarchive.org@send.elysiumhealth.com designates 149.72.236.79 as permitted sender) receiver=[receiver]; client-ip=149.72.236.79; envelope-from="[recipient]@send.elysiumhealth.com"; helo=o1385.shared.klaviyomail.com;
- Authentication-Results Authentication result
- [receiver]; dkim=pass header.d=elysiumhealth.com header.s=kl2 header.b=QZldGA12; dmarc=pass header.from=elysiumhealth.com policy.dmarc=quarantine; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=o1385.shared.klaviyomail.com; spf=pass ([receiver]: domain of bounces+20007143-b269-elysiuminboxarchive.org@send.elysiumhealth.com designates 149.72.236.79 as permitted sender) smtp.mailfrom="[recipient]@send.elysiumhealth.com"; arc=none smtp.remote-ip=149.72.236.79
Platform
- X-Kmail-Account
- R8xQKv
- X-Kmail-Message
- 01M7V8JPCK5DHC4B9X2AG9SE0B
- X-Kmail-Ops
- 01KX28G5HSKQA9CNV085MJW4AC
- X-SG-EID
- u001.Xv32TvI6iuV+tZ4vlqHO3HOP0TVxYBknYAX4/Mby5Th0PYwVlaUDVZEfaaXcBa1/i/If+231cWgIYCosFVQxSHrq0Qb9KqNmUmARiZmo9Vo1i5+u1Bk0yXunrSNNm6uguoBEtSmbNtNqMj7TnyEfnqbHeKaBHZejVAK/kjUq+XTYmF/DpcW+XqT2MBtzFCdpwmls9qNNvkme3O0c+j0jWYSjEU8t8gbMxkNihHJDEVAYJ/GDPIkvECYhtD/ulrKA
- X-SG-ID
- u001.SdBcvi+Evd/bQef8eZF3BiU3Zi1S53GtqGa3TWBmqe75yn5aYrkvkfG+ZGKrHRvqHEqNnYhXzKEMbIPUuNbUdfpjphyJI24ahdp5cMyD+gtd10HMsYQGG+9KCgoFZ++5EVWromru2FKCazsy6XMEltHTT+tgocK22oLF+t3/YWA7kSntJTFfg/GcbVhXwKuvSAPqF88zZOjDRLiPFb24LaPLA2mItQIVhtq2EbgCm+PziAM6gqPmCFwtVk+itaDgAbicCxV9q2C7dPZ1TWo6kuU1rbhwPUlRt6HU2I6fu8bCDUplgRnQPhPo9gLKH50cjaD58Gil4PvhJe8yyGXu7agXjED2An4cA83yXc6A8NWHFRGXfAHdp5/zcpq9iEQHwc9/ZZ6lqSrtJL9KXnzBPw==
- X-Entity-ID
- u001.lP8bpbcNOc7n5/pI/ei+9g==
Unsubscribe and feedback
- List-Unsubscribe
- <https://manage.kmail-lists.com/…>
- List-Unsubscribe-Post
- List-Unsubscribe=One-Click
- X-Report-Abuse
- Please report any spam or abuse to: [email protected]
Message
- Content-Type
- multipart/alternative; boundary=73a7ea0af9f59bf0af3764cb54e694255d4bf042a96c96813ec9045bd6d2
- Date
- Sun, 22 Nov 2026 13:15:53 +0000 (UTC)
- From
- Elysium Abstract <[email protected]>
- Mime-Version
- 1.0
- Message-ID
- <5F40pgJAT0WwpxiayF2pHA@geopod-ismtpd-18>
- Subject
- A human trial puts senolytics to the test
- Reply-To
- [email protected]
More from Elysium Health
All 43 emailsSimilar campaigns from other brands
Different brands running the same play. Compare any of them side by side.
Archived for reference and commentary. Elysium Health, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.